Omeros Announces Positive Data In Phase 1 Trial With OMS721

(RTTNews) - Omeros Corporation(OMER), Thursday reported positive clinical data in a Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 or MASP-2, which is an important regulator of the lectin pathway of the immune system. The company said that the subcutaneous administration of OMS721 achieved a high degree of lectin pathway inhibition.

Earlier this year, Omeros reported positive data using OMS721 in a well-established model of TMA.Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2.

Further, the company said a Phase 2 clinical program to study OMS721 in the treatment of thrombotic microangiopathies, a family of disorders that occurs in the microcirculation of the body's organs, most commonly the kidney and brain, is expected to begin enrollment in early 2014.